Search clinical trials for: Rebif® New Formulation (RNF) using RebiSmartTM

Total 22 results

EMD Serono

Completed

12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

Multiple Sclerosis

United States, Canada, Germany, Italy, Spain, Sweden
EMD Serono Research & Development Institute, Inc.

Completed

Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS)

Multiple Sclerosis

Lebanon, United States, Turkey, Sweden, Finland, France, Thailand, Serbia, Italy, United Kingdom, United Arab Emirates, Bulgaria, Belgium, Estonia, Argentina, Austria, Bosnia and Herzegovina, Canada, Croatia, Czechia, Georgia, Ger... and more
EMD Serono

Completed

Rebif New Formulation (RNF) Quality of Life (QOL) Study (RebiQoL)

Relapsing Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany

Completed

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting
Derming SRL

Completed

Evaluation of Tolerance and Trichological Efficacy of a Food Supplement

Telogen Effluvium
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

Multiple Sclerosis

Australia
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands; Merck A.E., Greece; Merck OY, Finland; Merck A.B., Sweden and other collaborators

Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (STAR)

Multiple Sclerosis, Relapsing Remitting

Greece
Merck KGaA, Darmstadt, Germany

Completed

Transition to Rebif New Formulation (TRANSFER)

Relapsing Multiple Sclerosis

France, Germany
Boehringer Ingelheim

Completed

Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers

Healthy
Merck KGaA, Darmstadt, Germany

Completed

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (REFLEXION)

Multiple Sclerosis | Clinically Isolated Syndrome

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Estonia, Germany, Latvia, Poland, Romania, Argentina, Finland, Israel, Greece, Czech Republic, Slovakia, Austria, Belgium, Canada, Lebanon, Morocco, Portugal, Serbia
Allergan

Completed

Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease

Dry Eye Syndromes

Canada, Australia
Boehringer Ingelheim

Completed

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Healthy

Germany
Alcon Research

Withdrawn

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

Ocular Hypertension | Open Angle Glaucoma
EMD Serono
Pfizer

Completed

RNF and Betaseron® Tolerability Study (REFORMS)

Relapsing Remitting Multiple Sclerosis (RRMS)

United States
Allergan

Completed

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

Dry Eye Disease (DED)

United States
Alcon Research

Completed

Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma
Boehringer Ingelheim

Completed

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Healthy
Allergan

Completed

A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery

Bilateral LASIK Surgery

Australia, Canada
Sanofi

Completed

Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Orphelia Pharma
Hospices Civils de Lyon; Institut National de la Santé Et de la Recherche Médicale... and other collaborators

Completed

Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy (SoluWest)

Infantile Spasms

France
Allergan

Terminated

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

Dry Eye Syndromes

United States
Chiesi Farmaceutici S.p.A.

Completed

Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients (ADO pMDI)

Asthma

Poland

3

Subscribe